Get the Stockscreener App
3.67
4.86%
0.17
After Hours:
3.67
Cellectis Adr stock is traded at $3.67, with a volume of 22,500.
It is up +4.86% in the last 24 hours and down -5.66% over the past month.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
See More
Previous Close:
$3.50
Open:
$3.6
24h Volume:
22,500
Relative Volume:
0.57
Market Cap:
$369.24M
Revenue:
$68.15M
Net Income/Loss:
$-67.60M
P/E Ratio:
-5.4491
EPS:
-0.6735
Net Cash Flow:
$-41.80M
1W Performance:
+1.10%
1M Performance:
-5.66%
6M Performance:
-27.18%
1Y Performance:
+149.66%
1-Day Range:
$3.5701
$3.7581
1-Week Range:
$3.45
$3.80
52-Week Range:
$1.3271
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
3.67 | 352.14M | 68.15M | -67.60M | -41.80M | -0.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Resumed | Jefferies | Buy |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| May-18-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-06-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-08-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-28-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-16-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Robert W. Baird | Outperform |
| Mar-06-20 | Downgrade | Goldman | Neutral → Sell |
| Oct-30-19 | Resumed | Guggenheim | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| May-24-19 | Resumed | Citigroup | Neutral |
| Mar-14-19 | Initiated | William Blair | Outperform |
| Dec-19-18 | Initiated | Goldman | Neutral |
| Jul-16-18 | Initiated | Barclays | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Sep-05-17 | Downgrade | SunTrust | Buy → Hold |
| Sep-05-17 | Reiterated | Wells Fargo | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Feb-28-17 | Initiated | Wells Fargo | Outperform |
| Apr-05-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Jul-20-15 | Initiated | BofA/Merrill | Buy |
| Apr-20-15 | Initiated | Jefferies | Buy |
| Apr-20-15 | Initiated | Piper Jaffray | Overweight |
View All
Cellectis Adr Stock (CLLS) Latest News
CLLS Stock Price, Quote & Chart | CELLECTISADR (NASDAQ:CLLS) - ChartMill
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Cellectis Reports Financial Results for the First Quarter 2026 - ChartMill
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting - ChartMill
European ADRs Open Lower As Telecoms And Biotech Split - Finimize
Cellectis stock rating held at outperform on allogeneic platform - Investing.com
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform - ChartMill
European ADRs Headed For A Strong Week In US Trading - Finimize
Monthly information on share capital and company voting rights - ChartMill
Citizens reiterates Cellectis stock rating on CAR-T progress - Investing.com
Cellectis earnings beat by $0.10, revenue topped estimates - Investing.com
Earnings call transcript: Cellectis beats Q4 2025 forecasts, stock rises - Investing.com
Cellectis (NASDAQ: CLLS) 2025 annual report shows losses and funding runway - Stock Titan
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - ChartMill
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - ChartMill
European ADRs Slipped As Biopharma Dragged The Pack - Finimize
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Jefferies assumes coverage on Cellectis stock with Buy rating - Investing.com
European ADRs Started The Week Higher In US Trading - Finimize
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView — Track All Markets
Traders are paying attention to the gapping stocks in Monday's session. - ChartMill
Clear Street initiates Cellectis stock with Buy rating on CAR-T potential - Investing.com
Working capital per share of Cellectis S.A. Sponsored ADR – NASDAQ:CLLS - TradingView — Track All Markets
European ADRs Inch Up As 3D Printer Materialise Leads Gains - Finimize
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Sahm
Arbitration ruling partially terminates Cellectis-Servier license agreement - Investing.com
European ADRs Stay Put As Novo Nordisk Slides - Finimize
Cellectis Adr Stock (CLLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):